Elevance Health Inc. (ELV) Tops Q4 EPS by 3c; Offers 2023 Guidance

Elevance Health Inc. (NYSE: ELV) reported Q4 EPS of $5.23, $0.03 better than the analyst estimate of $5.20. Revenue for the quarter came in at $39.67 billion versus the consensus estimate of $39.72 billion.

GUIDANCE:

Elevance Health Inc. sees FY2023 EPS of $32.60, versus the consensus of $32.69. Elevance Health Inc. sees FY2023 revenue of $164 billion, versus the consensus of $163.9 billion.

For earnings history and earnings-related data on Elevance Health Inc. (ELV) click here.

You May Also Be Interested In

• Delta Air Lines (DAL) Tops Q2 EPS by 3c, Beats on Revenue; Offers Guidance
• Penguin Solutions (PENG) Tops Q2 EPS by 28c, Beats on Revenue; Offers FY26 EPS Guidance
• Morgan Stanley Downgrades Cosmos Pharmaceuticals Corp. (3349:JP) (CSMYF) to Equalweight